Monte Rosa Therapeutics has announced a supply agreement with Johnson & Johnson to evaluate MRT-2359 combined with ERLEADA in metastatic castration-resistant prostate cancer. The company is initiating a Phase 2 trial testing this combination, whilst retaining control of the study and sponsorship. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Johnson & Johnson will supply ERLEADA, reducing Monte Rosa's cash requirements for sourcing the combination partner. Monte Rosa reported a full-year 2025 net loss of $38.63 million and remains unprofitable, with no profitability forecast over the next three years. Shareholders experienced substantial dilution over the past year, and an $83.63 million shelf registration indicates potential future equity issuance remains possible.

Monte Rosa Therapeutics reported a fourth-quarter loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.47 loss, representing a negative earnings surprise of 17.02%. This compares to earnings of $0.23 per share in the prior-year period. The biopharmaceutical company posted revenues of $2.78 million for the quarter ended December 2025, missing consensus estimates by 72.9%. Year-ago revenues totalled $60.65 million. Over the past four quarters, the company has surpassed consensus earnings estimates three times and topped revenue estimates three times. Monte Rosa shares have gained 4.3% year-to-date, outperforming the S&P 500's 2.1% decline. However, unfavourable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.

Monte Rosa Therapeutics has priced an underwritten public offering at $11.1 million to fund future research and operations. The biopharmaceutical company plans to use proceeds for clinical trials and research and development projects, particularly focusing on innovative cancer therapies. The offering aims to strengthen Monte Rosa's financial flexibility and enhance its competitive position in the biopharmaceutical market. Specific share details were not disclosed. The company expects the funding will help it capitalise on opportunities in the rapidly evolving sector.